Coxibs and Cardiovascular Disease
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The coxibs are a subclass of nonsteroidal antiinflammatory drugs (NSAIDs) designed to inhibit selectively cyclooxygenase-2 (COX-2).1 Their development was based on the hypothesis that COX-2 was the source of prostaglandins E2 and I2, which mediate inflammation, and that cyclooxygenase-1 (COX-1) was the source of the same prostaglandins in gastric epithelium, where they afford cytoprotection. Three coxibs — celecoxib, rofecoxib, and valdecoxib — have been approved for use by the Food and Drug Administration (FDA); a fourth, etoricoxib, has been approved by the European regulatory authority, and it and a fifth, lumiracoxib, are currently under consideration for FDA . . .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
Self-citationSchnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., Ehrsam, E., Gitton, X., Krammer, G., Mellein, B., Matchaba, P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16893-1 · Cited by 701
COX-2 and beyond: approaches to prostaglandin inhibition in human disease
FitzGerald, G. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1225 · Cited by 518
Self-citationCOX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, W. A., Stein, C. M., Daugherty, J. R., Hall, K., Arbogast, P. G., & Griffin, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11131-7 · Cited by 503
Farkouh, M. E., Kirshner, H., Harrington, R. A., Ruland, S., Verheugt, F. W., Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16894-3 · Cited by 490
Cited by
The immune response in atherosclerosis: a double-edged sword
Hansson, G. K., & Libby, P. (2006) · Nature Reviews Immunology · doi:10.1038/nri1882 · Cited by 2,182
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Wang, D., & DuBois, R. N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2809 · Cited by 1,793
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
Wang, B., Wu, L., Chen, J., Dong, L., Chen, C., Wen, Z., Hu, J., Fleming, I., & Wang, D. W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00443-w · Cited by 1,414
Authors/Task Force Members (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl001 · Cited by 1,336
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis
Trelle, S., Reichenbach, S., Wandel, S., Hildebrand, P., Tschannen, B., Villiger, P. M., Egger, M., & Juni, P. (2011) · BMJ · doi:10.1136/bmj.c7086 · Cited by 1,166
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Grosser, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27291 · Cited by 1,027
Felson, D. T. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp051726 · Cited by 986
Shibata, R., Sato, K., Pimentel, D. R., Takemura, Y., Kihara, S., Ohashi, K., Funahashi, T., Ouchi, N., & Walsh, K. (2005) · Nature Medicine · doi:10.1038/nm1295 · Cited by 982
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804
Patrono, C., Baigent, C., Hirsh, J., & Roth, G. (2008) · Chest · doi:10.1378/chest.08-0672 · Cited by 748
Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself?
Wallace, J. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00004.2008 · Cited by 716
Use of NSAIDs in treating patients with arthritis
Crofford, L. J. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4174 · Cited by 650
Recent developments in nitric oxide donor drugs
Miller, M. R., & Megson, I. L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707224 · Cited by 628
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases
Imig, J. D., & Hammock, B. D. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2875 · Cited by 614
Marret, E., Kurdi, O., Zufferey, P., Bonnet, F., & Warltier, D. C. (2005) · Anesthesiology · doi:10.1097/00000542-200506000-00027 · Cited by 577
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics
Ulrich, C. M., Bigler, J., & Potter, J. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1801 · Cited by 548
Bruyère, O., Cooper, C., Pelletier, J.-P., Branco, J., Luisa Brandi, M., Guillemin, F., Hochberg, M. C., Kanis, J. A., Kvien, T. K., Martel-Pelletier, J., et al. (2014) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2014.05.014 · Cited by 515
The role of inflammation in epileptogenesis
Vezzani, A., Friedman, A., & Dingledine, R. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.004 · Cited by 495
A Genome-wide RNAi Screen for Modifiers of the Circadian Clock in Human Cells
Zhang, E. E., Liu, A. C., Hirota, T., Miraglia, L. J., Welch, G., Pongsawakul, P. Y., Liu, X., Atwood, A., Huss, J. W., Janes, J., et al. (2009) · Cell · doi:10.1016/j.cell.2009.08.031 · Cited by 431
Conaghan, P. G. (2012) · Rheumatology International · doi:10.1007/s00296-011-2263-6 · Cited by 407
Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors
Grösch, S., Maier, T. J., Schiffmann, S., & Geisslinger, G. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj206 · Cited by 400
Molecular Targets of Dietary Polyphenols with Anti-inflammatory Properties
Yoon, J.-H., & Baek, S. J. (2005) · Yonsei Medical Journal · doi:10.3349/ymj.2005.46.5.585 · Cited by 381
Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., Arber, N., Levin, B., Meinert, C. L., Martin, B., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.764530 · Cited by 367
Epoxides and Soluble Epoxide Hydrolase in Cardiovascular Physiology
Imig, J. D. (2012) · Physiological Reviews · doi:10.1152/physrev.00021.2011 · Cited by 365
Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function
Cheng, Y. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27540 · Cited by 339
NSAIDs and Cancer Prevention: Targets Downstream of COX-2
Cha, Y. I., & DuBois, R. N. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131253 · Cited by 308
Hypertension in rheumatoid arthritis
Panoulas, V. F., Metsios, G. S., Pace, A. V., John, H., Treharne, G. J., Banks, M. J., & Kitas, G. D. (2008) · Rheumatology · doi:10.1093/rheumatology/ken159 · Cited by 303
Hershman, D. L., Unger, J. M., Greenlee, H., Capodice, J. L., Lew, D. L., Darke, A. K., Kengla, A. T., Melnik, M. K., Jorgensen, C. W., Kreisle, W. H., et al. (2018) · JAMA · doi:10.1001/jama.2018.8907 · Cited by 300
The role of cathepsins in osteoporosis and arthritis: Rationale for the design of new therapeutics
YASUDA, Y., KALETA, J., & BROMME, D. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.013 · Cited by 300
Cannabinoids in the management of difficult to treat pain
Russo, E. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1928 · Cited by 294
Natural anti-inflammatory agents for pain relief
Bost, J., Maroon, A., & Maroon, J. (2010) · Surgical Neurology International · doi:10.4103/2152-7806.73804 · Cited by 292
Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study
Deftereos, S., Giannopoulos, G., Angelidis, C., Alexopoulos, N., Filippatos, G., Papoutsidakis, N., Sianos, G., Goudevenos, J., Alexopoulos, D., Pyrgakis, V., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.017611 · Cited by 279
Mitchell, J. A., & Warner, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1929 · Cited by 279
Desai, S. J., Prickril, B., & Rasooly, A. (2018) · Nutrition and Cancer · doi:10.1080/01635581.2018.1446091 · Cited by 274
Wagner, K. M., McReynolds, C. B., Schmidt, W. K., & Hammock, B. D. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.06.006 · Cited by 270
De Caterina, R., & Massaro, M. (2005) · Journal of Membrane Biology · doi:10.1007/s00232-005-0783-2 · Cited by 130
Ruschitzka, F., Borer, J. S., Krum, H., Flammer, A. J., Yeomans, N. D., Libby, P., Lüscher, T. F., Solomon, D. H., Husni, M. E., Graham, D. Y., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx508 · Cited by 130
Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment
Imbimbo (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00019 · Cited by 75
Carlson, N. G., Hill, K. E., Tsunoda, I., Fujinami, R. S., & Rose, J. W. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.01.008 · Cited by 42
Metadata
- Authors
- FitzGerald, G. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-10-21
- Volume
- 351
- Issue
- 17
- Pages
- 1709-1711
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2012801178
- Cited by
- 899
- References
- 5
- FWCI
- 71.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.